Intra-Cellular Therapies Net Income 2013-2021 | ITCI

Intra-Cellular Therapies net income from 2013 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Intra-Cellular Therapies Annual Net Income
(Millions of US $)
2020 $-227
2019 $-148
2018 $-155
2017 $-98
2016 $-116
2015 $-105
2014 $-31
2013 $-27
2012 $-17
Intra-Cellular Therapies Quarterly Net Income
(Millions of US $)
2021-09-30 $-77
2021-06-30 $-69
2021-03-31 $-53
2020-12-31 $-61
2020-09-30 $-55
2020-06-30 $-64
2020-03-31 $-47
2019-12-31 $-41
2019-09-30 $-35
2019-06-30 $-37
2019-03-31 $-35
2018-12-31 $-41
2018-09-30 $-42
2018-06-30 $-37
2018-03-31 $-35
2017-12-31 $-30
2017-09-30 $-23
2017-06-30 $-18
2017-03-31 $-27
2016-12-31 $-27
2016-09-30 $-30
2016-06-30 $-31
2016-03-31 $-28
2015-12-31 $-29
2015-09-30 $-32
2015-06-30 $-22
2015-03-31 $-22
2014-12-31 $-15
2014-09-30 $-6
2014-06-30 $-5
2014-03-31 $-5
2013-12-31 $-8
2013-09-30 $-5
2013-06-30 $-8
2013-03-31 $-6
2012-12-31
2012-09-30 $-2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.475B $0.023B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.036B 8.91
Bio-Rad Laboratories (BIO.B) United States $17.472B 35.46
QIAGEN (QGEN) Netherlands $11.101B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.210B 0.00
Emergent Biosolutions (EBS) United States $2.527B 9.09
Arcus Biosciences (RCUS) United States $2.184B 0.00
Myovant Sciences (MYOV) United Kingdom $1.260B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.080B 0.00
Zymeworks (ZYME) Canada $0.522B 0.00
SQZ Biotechnologies (SQZ) United States $0.201B 0.00
Ambrx Biopharma (AMAM) United States $0.191B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81